BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AMT-260 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AMT-260\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06063850-8963@assetmemo.bio
DTSTAMP:20261121T005906Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AMT-260: Phase 1/2 readout est. (NCT06063850)
DESCRIPTION:AMT-260\, phase 1/2\, Epilepsy.\nStudy: AMT-260 Gene Therapy St
 udy in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy\nEs
 timated primary completion: 30 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amt-260#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06063850
URL:https://assetmemo.bio/drug/amt-260#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
